Conatus Pharmaceuticals Inc. (CNAT)
(Delayed Data from NSDQ)
$0.90 USD
+0.05 (5.88%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Histogen Inc. [CNAT]
Reports for Purchase
Showing records 21 - 40 ( 226 total )
Company: Histogen Inc.
Industry: Medical - Products
Healthcare - From NYC to Vienna - EASL Abstracts Galore: Attend our NASH Conference Mar. 28
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
Time for ENCORE to Bow Out; Downgrading to Neutral: PT to $1.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
NASH Weekly: Should You Go to EASL With Late Breakers Abstracts Revealed?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
4Q Recap: Expecting Three Data Readouts Within 6 Months; Affirm Buy, Reduce PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Healthcare - Part 1 - Which NASH Companies to See and Why at Our 31st ROTH Conference?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Healthcare: Kick off EASL by Joining our Battle of the NASH Thrones Investor Conference
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
NASH Splash No. 5: The STELLAR-4 Failure Is No Big Surprise to Us
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Healthcare: Biotech''s 2019 Untapped Market Opportunities: 2019 Is the Best NASH Year
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y